Related Experiment Video
Updated: Jul 18, 2025
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
12.2K
Epoprostenol Exposure During Pregnancy.
Emily E Naoum1, Carolyn LaVita2, Natasha Lopez3
1Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA.
Critical Care Explorations
|August 28, 2023
Summary
Current policies barring pregnant healthcare providers from caring for patients on inhaled epoprostenol lack data. Reviewing the literature can support removing these restrictions, ensuring equal employment and learning opportunities for pregnant providers.
Area of Science:
- Medical safety
- Occupational health
- Pulmonary medicine
Background:
- Many institutions restrict pregnant providers from caring for patients using inhaled epoprostenol.
- These restrictions are often based on limited scientific evidence.
Purpose of the Study:
- To review the literature regarding the safety of inhaled epoprostenol in obstetrical patients.
- To advocate for the removal of institutional policies that restrict pregnant providers from caring for patients receiving inhaled epoprostenol.
Main Methods:
- Literature review of studies on inhaled pulmonary vasodilators and their safety in pregnancy.
- Analysis of existing institutional policies and their evidentiary basis.
Main Results:
- The use of inhaled pulmonary vasodilators has increased over the past two decades.
- Evidence suggests these medications are safe for use in obstetrical patients.
- Current restrictions lack substantial data to support their necessity.
Conclusions:
- Removing restrictions on pregnant providers caring for patients on inhaled epoprostenol is warranted.
- This change would alleviate undue stress and ensure equitable employment and learning opportunities.
- Evidence supports the safety of inhaled epoprostenol for pregnant providers and their patients.
Keywords:
acute respiratory distress syndromecardiac critical carecritical carematernal critical careobstetric critical carepulmonary vasodilatorsMore Related Videos
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
213
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
213
01:07Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
200
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
200
01:33Hormonal Regulation
33.3K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.3K
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
493
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
493
02:07Oogenesis
63.8K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.8K